Cross-Sector entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention NovoCure Limited, the most common co-covered peer. The tracked stories average 7 original sources each. Optune Lua appears in 1 tracked Cross-Sector story from February 26, 2026.
1 verified story tracked
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention NovoCure Limited, the most common co-covered peer. The tracked stories average 7 original sources each. Optune Lua appears in 1 tracked Cross-Sector story from February 26, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Optune Lua. Shared-story counts are live from our verified record — not editorial picks.
NovoCure and Supernus Pharmaceuticals reported Q4 2025 results, highlighting a pivotal year for commercial expansion in oncology and CNS markets. Both companies are navigating the transition from R&D-heavy phases to sustained commercial growth following key regulatory milestones.
